Sutro Biopharma
STRO
59 hedge funds and large institutions have $101M invested in Sutro Biopharma in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 5 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 58 → 59 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.24% less ownership
Funds ownership: 51.54% → 48.3% (-3.2%)
51% less capital inflows, than outflows
Capital inflows: $8.04M | Capital outflows: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$3.48M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 3 |
BlackRock
New York
|
+$1.01M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$420K |
| 5 |
Morgan Stanley
New York
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
-$7.27M |
| 2 |
Sio Capital Management
New York
|
-$3.86M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.67M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$555K |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$235K |
STRO Hedge Fund Activity: Q3 2019 in Review
59 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2019, worth a combined $101M — down 25% from $134M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new STRO positions and 5 closed out — a net gain of 1 holder — while 24 added to existing stakes and 14 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $3.48M. The largest seller was Eventide Asset Management, cutting an estimated $7.27M.
- 59 institutional investors held Sutro Biopharma (STRO) as of Q3 2019, up from 58 in Q2 2019.
- Funds reported $101M of Sutro Biopharma stock for Q3 2019, down 25% quarter-over-quarter.
- 6 funds opened new Sutro Biopharma positions in Q3 2019 and 5 closed out, a net change of +1 holder.
- The largest Sutro Biopharma buyer in Q3 2019 was BVF Inc, an estimated $3.48M added.
- The largest Sutro Biopharma seller in Q3 2019 was Eventide Asset Management, an estimated $7.27M sold.
Based on aggregated 13F filings for Q3 2019.